Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.78 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.78 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.78 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.78 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.78 |
| ▸ | LY6K | Q17RY6 | 2/20 | 0.94 |
| ▸ | RAD52 | P43351 | 4/20 | 0.86 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.86 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.78 |
| ▸ | KDM1A | O60341 | 3/20 | 0.78 |
| ▸ | TOP2A | P11388 | 3/20 | 0.78 |
| ▸ | GLA | P06280 | 2/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | CASP1 | P29466 | 2/20 | 0.78 |
| ▸ | CASP7 | P55210 | 2/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.78 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.78 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24030236 | 0.97 | LY6K (1.00) | LY6KRAD52NCOA3TOP2BKDM1A | |
| Amsacrine SCHEMBL31237896 | 0.90 | TOP2B (0.95) | LY6KRAD52NCOA3TOP2BKDM1A | |
| Amsacrine SCHEMBL28336991 | 0.88 | TOP2B (1.00) | LY6KRAD52NCOA3TOP2BKDM1A | |
| Amsacrine SCHEMBL29350869 | 0.88 | TOP2B (1.00) | LY6KRAD52NCOA3TOP2BKDM1A | |
| Amsacrine SCHEMBL6256280 | 0.88 | TOP2B (1.00) | LY6KRAD52NCOA3TOP2BKDM1A | |
| Amsacrine SCHEMBL4047 | 0.88 | TOP2B (1.00) | LY6KRAD52NCOA3TOP2BKDM1A | |
| Amsacrine SCHEMBL29360354 | 0.88 | TOP2B (1.00) | LY6KRAD52NCOA3TOP2BKDM1A | |
| Amsacrine SCHEMBL31316257 | 0.87 | KMT2A (1.00) | LY6KRAD52NCOA3TOP2BKDM1A | |
| Amsacrine SCHEMBL1320825 | 0.87 | KMT2A (1.00) | LY6KRAD52NCOA3TOP2BKDM1A | |
| Amsacrine SCHEMBL8206192 | 0.86 | TOP2B (0.82) | LY6KRAD52NCOA3TOP2BKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263382-A1 | COMPOUNDS FOR INHIBITING LY6K AND METHODS OF USING SAME | HENRY M JACKSON FOUND ADVANCEMENT MILITARY MEDICINE INC (US) | 2025-08-21 | — | — | US | disclosed |
| US-12134601-B2 | Compounds for inhibiting LY6K and methods of using same | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20210009522-A1 | COMPOUNDS FOR INHIBITING LY6K AND METHODS OF USING SAME | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 2021-01-14 | — | — | US | disclosed |
| EP-3707127-A1 | COMPOUNDS FOR INHIBITING LY6K AND METHODS OF USING SAME | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263382-A1 | COMPOUNDS FOR INHIBITING LY6K AND METHODS OF USING SAME | LY6K, CCL2, CD74 | CHRM1 4816/4885DRD2 4430/4885ADRA2B 4331/4885 |
| US-12134601-B2 | Compounds for inhibiting LY6K and methods of using same | LY6K, CCL2, CXCL10 | CHRM1 4816/4885DRD2 4416/4885ADRA2B 3876/4885 |
| US-20210009522-A1 | COMPOUNDS FOR INHIBITING LY6K AND METHODS OF USING SAME | LY6K, CCL2, CXCL10 | CHRM1 4816/4885DRD2 4416/4885ADRA2B 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.